Skip to main content
. 2017 May 12;14(1):453–460. doi: 10.3892/ol.2017.6167

Figure 3.

Figure 3.

Overall survival of all eligible patients. (A) Outcomes following radiotherapy for patients with metastatic liver tumors. For the 24 patients, the median survival time was 45 months. (B) The 2- and 3-year overall survival rates were 87.5 and 87.5% in the ablative SBRT group, and 45.6 and 22.8% in the non-ablative SBRT group, respectively. Patients who received ablative SBRT showed significantly prolonged survival compared with those who received non-ablative SBRT (P=0.0261).